spiratory depression; adjust the dose of codeine if necessary. Ribociclib is a moderate CYP3A4 inhibitor. Codeine is primarily metabolized by CYP2D6 to morphine, and by CYP3A4 to norocodeine; norcodeine does not have analgesic properties. Concomitant use may result in an increase in codeine plasma concentrations, resulting in greater metabolism by CYP2D6 and increased morphine concentrations.
Acetaminophen; Chlorpheniramine; Dextromethorphan; Phenylephrine: (Moderate) Use caution if coadministration of ribociclib with dextromethorphan is necessary, as the systemic exposure of dextromethorphan may be increased resulting in increase in treatment-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and dextromethorphan is a CYP3A4 substrate.
Acetaminophen; Chlorpheniramine; Dextromethorphan; Pseudoephedrine: (Moderate) Use caution if coadministration of ribociclib with dextromethorphan is necessary, as the systemic exposure of dextromethorphan may be increased resulting in increase in treatment-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and dextromethorphan is a CYP3A4 substrate.
Acetaminophen; Codeine: (Moderate) Use caution if coadministration of ribociclib with codeine is necessary, as the systemic exposure of codeine may be increased resulting in an increase in treatment-related adverse reactions including sedation and respiratory depression; adjust the dose of codeine if necessary. Ribociclib is a moderate CYP3A4 inhibitor. Codeine is primarily metabolized by CYP2D6 to morphine, and by CYP3A4 to norocodeine; norcodeine does not have analgesic properties. Concomitant use may result in an increase in codeine plasma concentrations, resulting in greater metabolism by CYP2D6 and increased morphine concentrations.
Acetaminophen; Dextromethorphan: (Moderate) Use caution if coadministration of ribociclib with dextromethorphan is necessary, as the systemic exposure of dextromethorphan may be increased resulting in increase in treatment-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and dextromethorphan is a CYP3A4 substrate.
Acetaminophen; Dextromethorphan; Doxylamine: (Moderate) Use caution if coadministration of ribociclib with dextromethorphan is necessary, as the systemic exposure of dextromethorphan may be increased resulting in increase in treatment-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and dextromethorphan is a CYP3A4 substrate.
Acetaminophen; Dextromethorphan; Guaifenesin; Phenylephrine: (Moderate) Use caution if coadministration of ribociclib with dextromethorphan is necessary, as the systemic exposure of dextromethorphan may be increased resulting in increase in treatment-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and dextromethorphan is a CYP3A4 substrate.
Acetaminophen; Dextromethorphan; Phenylephrine: (Moderate) Use caution if coadministration of ribociclib with dextromethorphan is necessary, as the systemic exposure of dextromethorphan may be increased resulting in increase in treatment-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and dextromethorphan is a CYP3A4 substrate.
Acetaminophen; Dextromethorphan; Pseudoephedrine: (Moderate) Use caution if coadministration of ribociclib with dextromethorphan is necessary, as the systemic exposure of dextromethorphan may be increased resulting in increas |
